Skip to content
Oncology Research Hub

Milwaukee, Wisconsin

Cancer clinical trials in Milwaukee, WI

147 cancer studies are recruiting participants at sites in Milwaukee as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Milwaukee at a glance

  • 147 studies are recruiting at a site in Milwaukee.
  • By phase: Phase 1 (19), Phase 1/2 (11), Phase 2 (32), Phase 2/3 (6), Phase 3 (43), Phase 4 (2), No phase (10), Observational (24). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (65), industry (64), government (18).
  • By research area: Lymphoma (52), Breast Cancer (31), Lung Cancer (27), Prostate Cancer (18), Pancreatic Cancer (15), Melanoma (4).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Milwaukee

Basic details from each study's public record (the 30 most recently updated of 147). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05564377 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT06058377 · updated
  3. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Froedtert Hospital & the Medical College of Wisconsin
    Registry record
    NCT06638307 · updated
  4. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Zablocki Veterans Administration Medical Center
    Registry record
    NCT06995898 · updated
  5. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05334069 · updated
  6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05879926 · updated
  7. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study sites
    Ascension Columbia Saint Mary's Hospital - Milwaukee · Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center
    Registry record
    NCT06418204 · updated
  8. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT06748222 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Lung cancer studies recruiting in Milwaukee

  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center
    Registry record
    NCT04267848 · updated
  2. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT06096844 · updated
  3. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Aurora St. Luke's Medical Center
    Registry record
    NCT06758401 · updated
  4. Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

    • No phase
    • Ages 50 to 80
    • All sexes
    Sponsor
    bioAffinity Technologies Inc.
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07168993 · updated
  5. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Froedtert Hospital and the Medical College of Wisconsin
    Registry record
    NCT04198766 · updated
  6. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Ascension Columbia St. Mary's
    Registry record
    NCT06793215 · updated
  7. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07388524 · updated
  8. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT04181060 · updated
  9. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06890598 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Milwaukee

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Medical College of Wisconsin ( Site 0020)
    Registry record
    NCT06136624 · updated
  2. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Melanoma studies recruiting in Milwaukee

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07068074 · updated
  2. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Lymphoma studies recruiting in Milwaukee

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06724237 · updated
  2. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    The Medical College of Wisconsin
    Registry record
    NCT07221500 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Medical College of Wisconsin ( Site 0103)
    Registry record
    NCT06890884 · updated
  4. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT03739814 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Wisconsin
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05675410 · updated
  7. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06337318 · updated
  8. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06649812 · updated
  9. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Froedtert Hospital and the Medical College of Wisconsin
    Registry record
    NCT07101328 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Ask about studies near Milwaukee

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call